Stock Evaluator: NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. NAMS

$18.41 -1.10 -5.64%
November 20, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,745,039
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Commentary & Analysis


Financial Summary

Share Statistics NAMS Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $2,207.9 $203.5 57%
Shares Out (Mil) 124.1 55.2 66%
Institutional Ownership 98.9% 93.3% 83%
Float (Mil) 81.8 40.4 56%
Beta 0.14 1.05 10%
Avg Daily Volume (000s) 2,027 569 81%
Price Change
(52-week)
(52.3%) 38.8% 21%
Growth NAMS Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (96.3%) (10.7%) 2%
EPS (5yr) (4.1%) 15.4% 26
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (33.3%) (15.7%) 17%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 13 13 13
Current EPS ($0.462) ($1.481) ($2.028)
Month Ago EPS ($0.435) ($1.823) ($1.499)
# Rev Up 0 2 2
# Rev Down 1 1 1
Three Months Ago EPS ($0.441) ($1.818) ($1.479)
Year/Year Chg 230.0% (13.9%) (37.1%)
Financials NAMS Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $26 $40 15%
Net Income (TTM) (Mil) ($205) ($44) 6%
EPS (TTM) ($1.675) ($1.400) 16%
Operating Cash Flow (TTM) (Mil) ($151) ($35) 5%
Net Cash Flow (TTM) (Mil) ($115) $-0 14%
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) $1,772 $142 48%
Valuation NAMS Industry
Median
Percentile
(All Stocks)
P/B 3.50 1.96 75%
P/E na 16.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios NAMS Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 67.6% 96%
Net Margin (789.9%) (50.8%) 0%
ROA (27.8%) (47.0%) 17%
ROE (30.2%) (51.8%) 20%
Liabilities to Assets 8.3% 29.6% 4%
F-Score 4 3 33%

NewAmsterdam Pharma Company N.V. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors